Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
26 Março 2024 - 9:30AM
Telomir Pharmaceuticals, Inc.
(Nasdaq:TELO) (“Telomir” or the “Company”), a
pre-clinical-stage pharmaceutical company focused on the
development and commercialization of Telomir-1 as the first novel
small molecule to lengthen the DNA’s protective telomere caps in
order to potentially address age-related conditions, today
announced that Telomir and global animal health research company
Argenta have agreed to begin a three to six-months study on the
efficacy of Telomir-1 as a treatment for osteoarthritis and other
diseases of aging in canines.
The study will evaluate the efficacy of
Telomir-1 for mitigating the progression of osteoarthritis based on
symptomatic, radiographic, gross pathologic and histopathologic
evaluations. In addition, Telomir believes that this study could be
used as part of its pre-clinicial program for eventually evaluating
Telomir-1 in humans.
It is estimated that nearly 18 million canines
in the United States are affected by osteoarthritis. Of those, only
one third of the afflicted canines have a confirmed diagnosis and
are being treated for the disease. Current treatments only address
the symptoms of osteoarthritis, using behavioral therapies like
weight management and pain medications such as NSAIDs and
injectables.
“Osteoarthritis is the most common ailment in
canines yet there are currently no treatments that combat the
disease. As with human osteoarthritis, medical professionals are
limited to treatments that only help manage the symptoms,” stated
Chris Chapman, MD, Co-founder, Chairman, Chief Executive Officer
and President of Telomir Pharmaceuticals. “Working with Argenta, a
leading worldwide animal health research company, this study has
the potential to demonstrate both the efficacy of Telomir-1 as well
as a benign safety profile. We believe that Telomir-1 will offer an
attractive treatment for this indication. Just as important, we
believe that the results of this trial could be used to enable our
submission of an Investigation New Drug Application to the FDA to
study the potential effect of Telomir-1 on osteoarthritis in
humans.”
“Based on our initial research, we believe that
Telomir-1 can offer an effective disease-modifying therapy that
enhances the quality of life and mobility for canines with
osteoarthritis,” commented Dr. Michael Roizen, Special Advisor on
Age Reversal to Telomir Pharmaceuticals. “As with human
indications, we believe that Telomir-1 may have the potential to
treat age-related conditions in canines through telomere
regeneration as we believe it may enable the production of more
stem cells which essentially may allow the body, in effect, to
repair itself.”
To be added to the Telomir Pharmaceuticals email
distribution list, please email telomir@kcsa.com with TELO in the
subject line.
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a
pre-clinical-stage pharmaceutical company focused on the
development and commercialization of Telomir-1 as the first novel
small molecule to lengthen the DNA’s protective telomere caps in
order to potentially reverse age-related conditions. Telomeres are
the protective end caps of a chromosome made up of DNA sequences
and proteins. As humans age, telomeres shorten, with metal
reactivity accelerating the process, which presents us with an
increased chance of contracting a number of degenerative and
age-related diseases. Telomir’s goal is to develop and
commercialize Telomir-1 (which is proposed to be dosed orally) for
hemochromatosis (iron overload) and ultimately post-chemotherapy
recovery and a broader range of other age-related inflammatory
conditions such as osteoarthritis.
The Nobel Assembly at Karolinska Institute
(Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009
for the discovery of how chromosomes are protected by telomeres and
the enzyme telomerase.
Cautionary Note Regarding Forward-Looking
Statements
This press release and the statements of the
Company’s management related thereto contains “forward-looking
statements,” which are statements other than historical facts made
pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements may
be identified by words such as "aims," "anticipates," "believes,"
"could," "estimates," "expects," "forecasts," "goal," "intends,"
"may," "plans," "possible," "potential," "seeks," "will," and
variations of these words or similar expressions that are intended
to identify forward-looking statements. Any such statements in this
press release that are not statements of historical fact may be
deemed to be forward-looking statements. These forward-looking
statements include, without limitation, statements regarding
Telomir’s technologies potential in reversing age-related decline
and TELOMIR-1’s ability to result in an individual’s ability to
repair oneself by using TELOMIR-1. Any forward-looking statements
in this press release are based on Telomir's current expectations,
estimates and projections only as of the date of this release and
are subject to a number of risks and uncertainties (many of which
are beyond the Company’s control) that could cause actual results
(including the results of the proposed canine osteoarthritis study
referenced herein) to differ materially and adversely from those
set forth in or implied by such forward-looking statements. These
and other risks concerning Telomir's programs and operations are
described in additional detail in its registration statement on
Form S-1 and other SEC filings, which are on file with the SEC
at www.sec.gov and the Company’s website at
https://ir.telomirpharma.com. Telomir explicitly disclaims any
obligation to update any forward-looking statements except to the
extent required by law.
For further information, please contact:
KCSA Strategic Communications Phil Carlsontelomir@kcsa.com
Telomir Pharmaceuticalsinfo@Telomirpharma.com(813) 864-2558
Telomir Pharmaceuticals (NASDAQ:TELO)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Telomir Pharmaceuticals (NASDAQ:TELO)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024